Marinomed Biotech has announced plans for a Phase 4 trial of Carragelose iota-carrageenan nasal spray in healthcare professionals in contact with COVID-19 patients to study the ability of the nasal spray to reduce symptoms of viral respiratory infections, including SARS-CoV-2. The nasal spray is marketed as “Coldmaris Pro” in Austria, where the study will take place.
The 12-week clinical trial is expected to enroll 334 subjects who will spray one dose of Carregelose spray in the nose and three doses in the mouth three times per day. Subjects will be tested for COVID-19 and other respiratory infections once a week.
In April 2020, Marinomed announced that it was developing a Carregelose inhalation solution for the treatment of COVID-19 pneumonia. The company also recently announced launches of Carregelose nasal sprays in Italy and Austria.
Marinomed Chief Science Officer Eva Prieschl-Grassauer said, “Carragelose has earlier proven clinical activity towards coronavirus infections. Our scientists have shown that Carragelose is effective against SARS-CoV-2 in cell culture assays. Carragelose neutralizes the virus and can thus protect the cells from being infected. Successful clinical results will show that Carragelose can help us to fight the pandemic by adding an option to a still too small toolbox against this devastating COVID-19 infection.
Read the Marinomed Biotech press release.
